Federated Hermes’s Aligos Therapeutics ALGS Stock Holding History

Federated Hermes’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-26	Closed	-$488	–	2042
2023 Q3	$488	Sell	26 -39	-60%	-$864	﹤0.01%	2042
2023 Q2	$1.58K	Hold	65	–	–	﹤0.01%	2002
2023 Q1	$1.42K	Sell	65 -62	-49%	-$2.37K	﹤0.01%	2026
2022 Q4	$3.03K	Buy	127 +46	+57%	+$1.16K	﹤0.01%	1975
2022 Q3	$2K	Buy	+81	New	+$2.69K	﹤0.01%	1956
2022 Q2	–	Sell	-59,000	Closed	-$3.17M	–	2135
2022 Q1	$3.17M	Hold	59,000	–	–	0.01%	896
2021 Q4	$17.5M	Hold	59,000	–	–	0.03%	521
2021 Q3	$22.9M	Buy	59,000 +39,000	+195%	+$15.4M	0.04%	442
2021 Q2	$10.2M	Hold	20,000	–	–	0.02%	653
2021 Q1	$11.4M	Hold	20,000	–	–	0.02%	630
2020 Q4	$13.8M	Buy	+20,000	New	+$9.74M	0.03%	559

Other funds holding ALGS

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

ACP

Altitude Crest Partners Stamford, Connecticut $234M AUM

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Federated Hermes's ALGS Position: Q4 2023 in Review

Federated Hermes sold out of Aligos Therapeutics (ALGS) in Q4 2023, closing a stake of 26 shares — an estimated $488 sold.

Federated Hermes first reported a position in ALGS in Q4 2020 and held it in 11 quarters. The position peaked at $22.9M in Q3 2021. 39 funds tracked by Wall St. Rank hold ALGS as of Q4 2023.

Federated Hermes reported no remaining Aligos Therapeutics position as of Q4 2023 after selling out during the quarter.
Federated Hermes sold 26 Aligos Therapeutics shares in Q4 2023, an estimated $488.
Federated Hermes first reported a position in Aligos Therapeutics in Q4 2020 and held it in 11 quarters.
Federated Hermes's Aligos Therapeutics position peaked at $22.9M in Q3 2021.
39 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q4 2023.

Based on Federated Hermes's 13F filing for Q4 2023, filed 31 Jan 2024.